Topiramate + Phentermine: An excessively dangerous appetite-suppressant combination

Prescrire International

Volumn 22, Issue 136, 2013, Pages 61-64

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; METFORMIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENTERMINE RESIN; PLACEBO; TOPIRAMATE;

ACUTE CORONARY SYNDROME; AGITATION; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATAXIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLEFT PALATE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MISUSE; DRUG POTENTIATION; DRUG SAFETY; EUPHORIA; EUROPEAN UNION; FATIGUE; FETOTOXICITY; FETUS MALFORMATION; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HALLUCINATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MANIA; MEDICAL DOCUMENTATION; MEMORY DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; MYOPIA; NAUSEA; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OFF LABEL DRUG USE; PRENATAL DRUG EXPOSURE; PSYCHOMOTOR RETARDATION; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SUICIDE; TACHYCARDIA; TERATOGENICITY; TREMOR; UNITED STATES; UROLITHIASIS; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; DRUG APPROVAL; DRUG COMBINATIONS; EUROPEAN UNION; FEMALE; FRUCTOSE; HUMANS; OBESITY; OVERWEIGHT; PHENTERMINE; PREGNANCY; UNITED STATES;

EID: 84875832818     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. U.S. Food and Drug Administration. Center for Drug Evaluation and Research "FDA Briefing information for the February 22, 2012 meeting of the endocrinologic and metabolic drugs advisory committees": 132 pages.
2. Allisson DB et al. "Controlled-release phentermine+ topiramate in severely obese adults: a randomized controlled trial (Equip)" Obesity 2012; 20: 330-342.
3. Gadde KM et al. "Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (Conquer): a randomised, placebocontrolled, phase 3 trial" Lancet 2011; 377: 1341-1352.
4. Garvey WT et al. "Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (Sequel): a randomized, placebo-controlled, phase 3 extension study" Am J Clin Nutr 2012; 95(2): 297-308.
5. "Dexamfetamine sulfate". In: Martindale the Complete Drug Reference. www.medicinescomplete.com accessed 16 July 2012: 10 pages.
6. "Phentermine". In: "Martindale the complete Drug Reference". www.medicinescomplete.com accessed 16 July 2012: 4 pages.
7. Prescrire Editorial Staff "Severe heart valve disease on appetite suppressants" Prescrire Int 1998; 7 (33): 19-20.
8. Prescrire Editorial Staff "Anorectic drugs: managing the risk of valve disease and endocarditis" Prescrire Int 1998; 7 (183): 116-117.
9. Prescrire Editorial Staff "Valve disease due to appetite suppressants (cont'd)" Prescrire Int 1999; 8 (42): 115.
10. Prescrire Rédaction "12-1-10. Patients sous topiramate ou zonisamide" Rev Prescrire 2012; 32 (350 suppl. interactions médicamenteuses).
11. Vivus "QNEXÅ (phentermine/topiramate) extended release capsules - Endocrinologic and metabolic drugs advisory committee meeting" February 2012: 137 pages.
12. U.S. Food and Drug Administration "Endocrinologic and metabolic drugs advisory committee meeting Qnexa (phentermine/topiramate) NDA 22580" 22 February 2012: 74 pages.
13. Vivus "VI-0521 (Qnexå) advisory committee briefing document" 22 February 2012: 365 pages.
14. EMA "Refusal of marketing authorisation for Qsiva (phentermine) topiramate" 18 October 2012: 2 pages.